Section 1042 Rollover

Showing 93 articles
Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

Deutsche Bank Hits 2025 Targets, Sets Sights on Higher Returns Amid Strategic Shift

Deutsche Bank reported meeting its key 2025 financial objectives, including a 10.3% return on tangible equity, and outlined a path to boost profitability above 13% by 2028. The update, delivered during a fixed income call, highlighted revenue growth, cost discipline, and a strengthened balance sheet, even as management signaled caution on parts of the commercial real estate market.